Public health impact and cost-effectiveness of implementing gender-neutral immunization with the nonavalent human papillomavirus vaccine in South Korea Authors: Sangrak Bae, Ji Hyun Park, Seyoung Oh, Gyongseon Yang, Wei (Vivian) Wang, Andrew Pavelyev, Isaya Sukarom Published: 2025 ABSTRACT ABSTRACTThis study assessed the impact and cost-effectiveness of gender-neutral immunization with the nonavalent human papillomavirus (HPV) vaccine in South Korea. An established dynamic transmission model of HPV epidemiology was adapted to the South Korean population. Vaccinating both girls and boys with the nonavalent HPV vaccine was compared to the currently administered program of vaccinating girls only with the quadrivalent vaccine. Compared to vaccination of girls only with the quadrivalent HPV vaccine, gender-neutral vaccination with the nonavalent HPV vaccine was projected to prevent 1,282,415 cases of cervical intraepithelial neoplasia grade 1 (CIN1), 918,384 cases of CIN2/3, 36,248 cases of cervical cancer, and 9,313 cervical cancer deaths in females over 100 years. Gender-neutral vaccination was projected to reduce HPV-related vaginal, vulvar, anal, and head & neck cancers in females by 4.8–8.2%, in addition to reductions of 14.6% and 15.8% in genital warts and recurrent respiratory papillomatosis, respectively. In males, gender-neutral vaccination was projected to prevent 666,182 cases of genital warts, 7,422 cases of RRP, 995 cases of anal cancer, 2,441 cases of head & neck cancer, and 122 cases of penile cancer. The incremental cost-effectiveness ratio (ICER) was ₩38.9 million per quality-adjusted life year (QALY), which is below the accepted cost-effectiveness threshold in South Korea. These findings suggest that gender-neutral vaccination with the nonavalent HPV vaccine would reduce the public health burden of HPV disease in both females and males in South Korea and would be cost-effective under base case assumptions about vaccine price and coverage of boys.KEYWORDS: Cancer, gender-neutral vaccination, human papillomavirus, papillomavirus vaccines, 9vHPV Introduction Worldwide, human papillomavirus (HPV) infection is responsible for 25–50% of cases of vulvar, penile, and head & neck cancers (primarily oropharyngeal, but also oral and laryngeal), 80–90% of cases of vaginal and anal cancers,1 and virtually all cases of cervical cancer.2 HPV strains are categorized as either low-risk (benign) or high-risk (oncogenic).3 Low-risk types 6 and 11 are responsible for approximately 90% of genital wart cases and most cases of recurrent respiratory papillomatosis (RRP).3,4 High-risk HPV types, which include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, are primarily responsible for precancerous and cancerous lesions of the anogenital area in both sexes.1,5 In South Korea, the prevalence of HPV infection has been estimated at 10–15% among young women aged 19–20 and at 38.8% among women with sexual experience.6,7 A meta-analysis also found that HPV infection was present in 20.4% of women with a normal cervix, 85.6% of those with high-grade cervical intraepithelial neoplasia (CIN2/3/CIS), and 88.3% of those with cervical cancer, with HPV-16, 18, and 58 among the most common high-risk types in South Korea.8 Three HPV vaccines are available in South Korea: a bivalent vaccine targeting high-risk HPV types 16 and 18; a quadrivalent (4vHPV) vaccine targeting low-risk types 6, 11 and high-risk types 16, and 18; and a nonavalent (9vHPV) vaccine protecting against types 6, 11, 16, and 18, in addition to high-risk types 31, 33, 45, 52, and 58.9–11 Since June 2016, the bivalent and quadrivalent HPV vaccines have been included in the national immunization program (NIP) and are recommended for girls 12 years of age in a 2-dose schedule.12 There is currently no routine HPV vaccination program for boys, and though the nonavalent vaccine is available in South Korea, it is not included in the NIP and must be purchased privately.12 The 9vHPV vaccine is particularly important because it extends protection to five additional high-risk HPV types (31, 33, 45, 52, and 58), providing broader coverage that better reflects the type distribution observed in Korea.11 As of 2019, 72% of the target age group had received at least one dose of the HPV vaccine.13 Observational studies of HPV vaccination of girls extending up to 14 years after the start of vaccination show substantial reductions in cervical intraepithelial neoplasia (CIN) among females and anogenital warts in both sexes.14,15 However, because the progression from HPV infection to cancer takes several decades, the effects of vaccination on HPV-related cancers will not appear until much later.16 This necessitates analyzing the long-term epidemiologic and economic implications of HPV vaccination using mathematical models.17 Previous modeling studies have indicated that gender-neutral vaccination (i.e., vaccination of both girls and boys) against HPV types 6, 11, 16, and 18 would be associated with substantial additional reductions in the incidence of HPV-related diseases;18–20 however, these studies were conducted outside of South Korea. Evidence specific to the Korean context, where the national program is girls-only and does not include the 9vHPV vaccine, remains limited. Generating context-specific data is critical, as NIP policy decisions require robust local evidence to ensure that recommendations are both cost-effective and aligned with the country’s epidemiological and healthcare realities. Strengthening the evidence base for Korea will therefore be essential to guide policymakers in evaluating whether broader vaccine coverage – such as inclusion of boys or introduction of the 9vHPV vaccine – would provide meaningful public health benefits and justify programmatic changes. The goal of this study was to apply an established model to assess the health and economic impact and cost-effectiveness of gender-neutral HPV vaccination of 12-year-old girls and boys in South Korea. Materials and methods Model overview The analysis was conducted using a previously published dynamic transmission model of the epidemiology of HPV infection and disease development.21,22 The model calculated the epidemiologic burden and healthcare cost of HPV infections attributable to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in an age-structured South Korean population over a 100-year time horizon. Two vaccination strategies were compared: immunization of 12-year-old boys and girls with the 9vHPV vaccine and immunization of 12-year-old girls only with the 4vHPV vaccine. Both costs and utility benefits were discounted at an annual rate of 4.5% according to the Health Insurance Review and Assessment (HIRA) Service’s Guidelines for Pharmaceutical and Economic Evaluation.23 Since this was a modeling study using de-identified data as model inputs, no ethical approval was required. Model description The model consists of a demographic model and a series of epidemiologic models. The demographic model simulates the movement of persons into and out of the model. Persons entering the model move between successive age groups and eventually exit the model at age- and gender-specific rates. The epidemiologic models simulate the transmission of HPV and the occurrence of diseases related to HPV. The population was divided into distinct epidemiologic compartments, defined according to the host’s status concerning HPV infection and HPV-related disease. Changes in the number of persons in each compartment and movements between compartments were represented by a system of ordinary differential equations. Model inputs Population demographics and behavior Demographic and behavioral parameters were population size, mortality rates by age category, and sexual behavior. Population demographics were from Statistics Korea (KOSIS).24 In 2021, the population size was 51,628,117, including 25,837,747 females and 25,790,370 males. Sexual behavior was categorized into low-, medium-, and high-risk groups according to the mean number of sexual partners per year: low (0–1 partners), medium (2–4 partners), and high (≥5 partners). Base case values for the percentage of the population in each risk category, by gender, and mean number of sexual partners per year, by gender and by age category, are presented in Supplementary Table S1. Sexual mixing among age cohorts was set at 0.4 between sexual debut and cessation and at 0.1 after cessation, where 0 represents no mixing and 1 represents maximal mixing.25 Sexual mixing among different sexual activity groups was set at 0.5.25 HPV-related disease and treatment patterns The modeled HPV-related diseases included type-specific outcomes for cervical, vaginal, vulvar, penile, anal, and head & neck cancers, CIN 1/2/3, genital warts, and RRP. The input parameters for cervical cancer were the percentage of the female population receiving a hysterectomy annually by age category,24 annual cervical cancer mortality rates by cancer stage (local, regional, distant), the percentage of the female population with cervical cancer seeking treatment by disease stage, and the percentage of CIN cases treated by CIN stage (1, 2, 3, CIS).26 The same mortality and treatment parameters were applied to vaginal, vulvar, anal, head & neck, and penile cancers. The percentage of precancerous cases treated for vaginal and vulvar cancer was categorized by stage (VaIN1, VaIN2/3, and CIS for vaginal cancer; VIN1, VIN2/3, and CIS for vulvar cancer). The annual mortality rate for RRP (laryngeal papillomatosis) was 0.01 in females and males.27,28 The percentage of genital wart cases treated was 80% in females and males.12 Cervical cancer screening parameters The percentage of females receiving a follow-up screening test after an abnormal PAP smear diagnosis (60.8%) was from Park & Park, and the percentage of females receiving a gynecological screening test at least once in their lifetime (68.45%) was from the National Cancer Center.29,30 The percentage of females screened for cervical cancer by age category in the past year was from KOSIS.24 The sensitivity of PAP screening for CIN1, CIN2, and CIN3 was 0.77, 0.97, and 0.97, respectively.31 The specificity of PAP screening was 0.977,32 and the sensitivity and specificity of colposcopy were 0.96 and 0.48, respectively.33 Vaccine properties Values for the degree of protection conferred by the vaccine were the medians of values from published clinical trials.34–39 Values differed for oncogenic HPV types (types 16, 18, 31, 33, 45, 52, and 58) versus low-risk types (types 6 and 11) in males36 and females.35,39 The degree of protection values also differed for each cancer. Vaccination of males was assumed to protect against transmission of male genital infections to females; correspondingly, vaccination of females was assumed to protect against transmission of genital infections to males. The degree of protection differed for transient HPV infection, for persistent infection, and for progression to neoplasia. Values for protection against transient infections differed for males and females for all cancers; values for protection against persistent infections differed for males and females for anal and head & neck cancers only. Breakthrough infections were assumed to be transmissible. In each case, the duration of protection was assumed to be lifelong. Vaccination strategy The percentage of females and males 12 years of age who received the vaccine was assumed to be 90% and 70%, respectively. The percentage of those who completed the 2-dose schedule after receiving the first dose was assumed to be 100%. Costs Costs are presented in South Korean won (₩) 2022 (Supplementary Table S2). The cost of each vaccination was the cost of the vaccine per dose (assumed to be ₩100,000) plus the cost of vaccine administration (₩19,610, set by the Korea Disease Control and Prevention Agency (KDCA)), for a total of ₩119,610. The costs per episode of care for HPV-related cancers and genital warts were from the National Evidence-based Healthcare Collaborating Agency.40 The costs of screening and diagnostic tests for cervical and vaginal cancers were the reimbursement fees for an obstetrician-gynecologist office visit, colposcopy, and biopsy. Cited costs were inflated to 2022 values using the Statistics Korea Consumer Price Index. Cost-effectiveness Quality-adjusted life year (QALY) values were calculated using health utility values broken down by age and sex for individuals without HPV-related diseases and by sex and disease stage for individuals with HPV-related diseases. The source for persons without HPV-related disease was the 5th Korea National Health and Nutrition Examination Survey (KNHANES). Health utilities by sex and disease stage for individuals with HPV-related disease were from published sources.41–44 The accepted cost-effectiveness threshold of ₩40 million was from the National Evidence-based Healthcare Collaborating Agency.26 Model outputs Health outcomes were the incidence of cervical lesions (CIN 1/2/3) and of cancers of the cervix, vagina, vulva, penis, anus, and head & neck, as well as genital warts and RRP. Mortality rates were projected for each cancer type and for RRP. Costs and QALYs associated with each HPV-related disease were also generated. Model calibration The model was calibrated to HPV-related cancer incidence and mortality rates per 100,000 persons per year (Supplementary Table S3). Incidence rates of HPV-related cancers were from KOSIS,24 except for the incidence of head & neck cancer.45 Incidence rates of genital warts were from the HIRA Bigdata Open portal.46 Mortality rates for cancers of the vagina, vulva, penis, anus, oral cavity, and oropharynx were from Sung et al.47 Mortality rates for cancers of the cervix, head & neck, and larynx were from KOSIS.24 Sensitivity analysis The following parameters were varied in a one-way sensitivity analysis based on prior economic evaluations and on their relevance and uncertainty for South Korea: the discount rate (base case value, 4.5%) was varied at 0%; the vaccine coverage rate for males (base case value, 70%) was varied at 90%; and vaccine price was varied by ±10%. Discounting strongly influences long-term preventive interventions and has been identified repeatedly as a key driver of cost-effectiveness in HPV vaccination models.48–50 The discount rate is used to convert future costs and health benefits into present values. A higher discount rate lowers the present value of long-term health gains, which can significantly affect the incremental cost-effectiveness ratio (ICER). We varied male vaccine coverage because coverage rates influence both the extent of disease prevention and the potential for herd immunity. Consequently, the incremental benefit of vaccinating boys depends on current and projected female coverage as well as achievable male uptake. Male coverage is also a policy-relevant parameter under consideration by Korean health authorities. Including this parameter enables the analysis to capture realistic implementation scenarios and to assess how changes in uptake could affect both health outcomes and economic value. Finally, we varied vaccine price because vaccine acquisition cost is commonly among the most influential cost parameters in ICER estimates across settings. A higher vaccine price increases the overall cost of the immunization program, which can reduce its cost-effectiveness. Since vaccine procurement represents a significant financial commitment for the government, this parameter was included to reflect its direct impact on budgetary decisions. In addition, a sexual behavior scenario analysis was conducted, using higher values for the percentage of the population in the high-risk group and the mean number of sexual partners per year in the high-risk group in both males and females (see Supplementary Table S1. Sexual behavior model inputs).26 Results Public health impact Incident cases and deaths due to HPV-related diseases The projected incidence of cases and deaths due to HPV-related disease is shown in Supplementary Figures S1-S7. In females, the incidence of CIN1 related to oncogenic 9vHPV vaccine types was projected to begin declining within about 5 years, reaching a minimum within about 50 years of about 6 per 100,000 with the 9vHPV vaccine and 70 per 100,000 with the 4vHPV vaccine. The incidence of cervical cancer and cervical cancer deaths related to oncogenic 9vHPV types followed a similar pattern, with declines projected to begin within about 25 years. A similar pattern was observed in the projections for the incidence of cancers of the anus and head & neck related to oncogenic 9vHPV types, and for incident cases of genital warts and RRP related to HPV types 6 and 11, but with a greater separation between the curves for 9vHPV and 4vHPV vaccines in males than in females. Incident cases and deaths avoided with gender-neutral immunization with the 9vHPV vaccine Relative to girls-only 4vHPV vaccination, gender-neutral immunization with the 9vHPV vaccine was projected to avert about 1.28 million cases of CIN 1, 918,384 cases of CIN 2/3, and 36,248 cases of cervical cancer over 100 years, representing reductions by 69.2%, 59.1%, and 17.6% (Table 1). Table 1.Projected cumulative reduction in incident cases of HPV diseases related to 9vHPV vaccine types relative to 4vHPV vaccination over 100 years. Number (%) of cases avertedaOver 5 yearsOver 25 yearsOver 50 yearsOver 100 yearsCervical Cancer0 (0.0)173 (0.2)4,743 (3.5)36,248 (17.6) CIN 1132 (0.1)127,767 (24.6)490,689 (50.8)1,282,415 (69.2) CIN 2/3125 (0.1)93,594 (17.9)352,784 (40.6)918,384 (59.1)Vaginal cancer0 (0.0)0 (0.0)7 (0.5)130 (5.5)Vulvar cancer0 (0.0)0 (0.0)6 (0.5)149 (7.1)Anal cancer Female0 (0.0)0 (0.0)31 (0.5)456 (4.8) Male0 (0.0)1 (0.0)73 (1.7)995 (13.9)Head & neck cancer Female0 (0.0)0 (0.0)32 (0.8)482 (8.2) Male0 (0.0)2 (0.0)185 (1.7)2,441 (14.5)Penile cancer0 (0.0)0 (0.0)20 (2.8)122 (12.9)Genital wartsb and HPV 6/11-related CIN 1 Genital warts, female11 (0.0)6,398 (2.7)21,530 (6.8)55,419 (14.6) Genital warts, male221 (0.1)62,870 (6.8)231,975 (16.5)666,182 (32.6) CIN 116 (0.0)19,005 (2.9)65,281 (7.5)164,546 (16.0)RRPb Female0 (0.0)154 (1.9)721 (6.3)2,218 (15.8) Male2 (0.1)636 (4.6)2,513 (12.3)7,422 (27.0)4vHPV, quadrivalent human papillomavirus; 9vHPV, nonavalent human papillomavirus; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; RRP, recurrent respiratory papillomatosis.aCases of HPV diseases averted with gender-neutral 9vHPV vaccination versus 4vHPV vaccination of girls only. Except where indicated, cases are related to 9vHPV oncogenic vaccine types.bCases of genital warts and RRP related to HPV types 6 and 11. Projected cumulative reduction in incident cases of HPV diseases related to 9vHPV vaccine types relative to 4vHPV vaccination over 100 years. 4vHPV, quadrivalent human papillomavirus; 9vHPV, nonavalent human papillomavirus; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; RRP, recurrent respiratory papillomatosis. aCases of HPV diseases averted with gender-neutral 9vHPV vaccination versus 4vHPV vaccination of girls only. Except where indicated, cases are related to 9vHPV oncogenic vaccine types. bCases of genital warts and RRP related to HPV types 6 and 11. Projected percent reductions in vaginal cancer, vulvar cancer, anal cancer, and head & neck cancer were in the range of 4.8–8.2% among females, while reductions in female genital warts and RRP were 14.6% and 15.8%, respectively. In males, reductions of 12.9–14.5% in cases of penile cancer, anal cancer, and head & neck cancer were projected, in addition to a reduction of 32.6% and 27.0% in cases of male genital warts and RRP, respectively. The projected cumulative reduction in deaths related to 9vHPV vaccine types (Table 2) was 15.3% due to cervical cancer, 4.2–7.3% for other cancers in females, and 11.7–13.5% for cancers in males. Table 2.Projected cumulative reduction in deaths related to 9vHPV vaccine types relative to 4vHPV vaccination over 100 years. Number (%) of deaths avertedaOver 5 yearsOver 25 yearsOver 50 yearsOver 100 yearsCervical cancer0 (0.0)17 (0.1)935 (2.4)9,313 (15.3)Vaginal cancer0 (0.0)0 (0.0)2 (0.3)57 (4.8)Vulvar cancer0 (0.0)0 (0.0)1 (0.2)49 (6.2)Anal cancer Female0 (0.0)0 (0.0)6 (0.3)124 (4.2) Male0 (0.0)0 (0.0)18 (1.0)361 (12.6)Head & neck cancer Female0 (0.0)0 (0.0)4 (0.5)87 (7.3) Male0 (0.0)0 (0.0)25 (1.3)426 (13.5)Penile cancer0 (0.0)0 (0.0)4 (1.8)39 (11.7)RRP Female0 (0.0)4 (1.1)29 (4.7)98 (13.1) Male0 (0.0)19 (2.8)101 (9.6)325 (23.1)4vHPV, quadrivalent human papillomavirus; 9vHPV, nonavalent human papillomavirus; RRP, recurrent respiratory papillomatosis.aDeaths due to HPV diseases with gender-neutral 9vHPV vaccination versus 4vHPV vaccination of girls only. Projected cumulative reduction in deaths related to 9vHPV vaccine types relative to 4vHPV vaccination over 100 years. 4vHPV, quadrivalent human papillomavirus; 9vHPV, nonavalent human papillomavirus; RRP, recurrent respiratory papillomatosis. aDeaths due to HPV diseases with gender-neutral 9vHPV vaccination versus 4vHPV vaccination of girls only. Economic impact Costs The total cumulative costs of treating HPV diseases over 100 years were ₩2,387 billion with 4vHPV immunization of girls only and ₩2,113 billion with gender-neutral immunization with the 9vHPV vaccine. The biggest drivers of costs with 4vHPV vaccination of girls only were the costs of treating cervical cancer (₩883.2 billion), CIN1 (₩170.4 billion), and CIN2/3 (₩530.6 billion) in females, and genital warts (₩261.6 billion) and head & neck cancer (₩120.7 billion) in males. These treatment costs were all lower with gender-neutral immunization with the 9vHPV vaccine: cervical cancer (₩852.4 billion), CIN1 (₩109.6 billion), and CIN2/3 (₩395.9 billion) in females, and genital warts (₩231.9 billion) and head & neck cancer (₩117.6 billion) in males. Most of the treatment costs avoided with gender-neutral 9vHPV vaccination were for treatment of HPV disease related to types 31, 33, 45, 52, and 58, with these costs averted peaking 20–30 years after the start of vaccination (Figure 1). Projected treatment costs avoided over 100 years by gender-neutral immunization with the 9vHPV vaccine. HPV, human papillomavirus; KRW, South Korean won (₩). Red, healthcare costs due to HPV 31, 33, 45, 52, 58-related diseases; blue, healthcare costs due to HPV 6/11-related diseases; green, healthcare costs due to HPV16/18-related diseases. Cost-effectiveness The projected savings in treatment costs over 100 years with gender-neutral vaccination with the 9vHPV vaccine totaled ₩274.1 billion. The costs of vaccination were ₩1,706.9 billion greater, for a net increase in costs with gender-neutral vaccination of ₩1,432.8 billion. Comparing gender-neutral 9vHPV vaccination with girls-only 4vHPV vaccination, the ICER was ₩38.9 million per QALY, i.e., gender-neutral 9vHPV vaccination was cost-effective in the base case analysis (Table 3). Table 3.Cost-effectiveness of gender-neutral immunization with the 9vHPV vaccine compared with the 4vHPV vaccinea.StrategyDiscounted total cost per person (₩)QALYs per personIncremental cost per person (₩)Incremental QALYs per personIncremental cost per QALY (₩/QALY)Base case analysis Female-only with 4vHPV vaccine658,85020.93391––– Gender-neutral with 9vHPV vaccine686,62720.9346327,777.30.0007138,863,930Sexual behavior scenario analysis Female-only with 4vHPV vaccine657,83220.92313––– Gender-neutral with 9vHPV vaccine685,35020.9238927,517.90.0007636,418,4974vHPV, quadrivalent human papillomavirus; 9vHPV, nonavalent human papillomavirus; QALY, quality-adjusted life year.aCost-effectiveness of gender-neutral 9vHPV vaccination versus 4vHPV vaccination of girls only, over 100 years. Cost-effectiveness of gender-neutral immunization with the 9vHPV vaccine compared with the 4vHPV vaccinea. 4vHPV, quadrivalent human papillomavirus; 9vHPV, nonavalent human papillomavirus; QALY, quality-adjusted life year. aCost-effectiveness of gender-neutral 9vHPV vaccination versus 4vHPV vaccination of girls only, over 100 years. Sensitivity analysis In the one-way sensitivity analysis, the ICER was most sensitive to vaccine price and to male vaccine coverage: increasing the 9vHPV vaccine price by 10% increased the ICER to ₩45.2 million per QALY, and increasing the vaccine coverage rate in males to 90% increased the ICER to ₩45.6 million per QALY (Figure 2). In contrast, changing the discount rate to 0% reduced the ICER to ₩9.0 million. In the sexual behavior scenario analysis, the ICER value for the comparison of gender-neutral 9vHPV vaccination with girls-only 4vHPV vaccination was ₩36.4 million per QALY (Table 3). One-way sensitivity analysis of ICERs for gender-neutral immunization with the 9vHPV vaccine. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year. Discussion The results from this modeling analysis show substantial reductions in cervical cancer cases and deaths related to oncogenic 9vHPV vaccine types when comparing gender-neutral 9vHPV immunization of 12-year-old boys and girls with 4vHPV immunization of 12-year-old girls only. Reductions in anal cancer, head & neck cancer, genital warts, and RRP related to HPV types 6 and 11 were greater in males than in females, suggesting that males benefit directly from vaccination beyond the population herd effect. In addition to these public health benefits, gender-neutral 9vHPV vaccination was projected to be cost-effective, resulting in an ICER of ₩38.9 million per QALY, below South Korea’s ₩40 million cost-effectiveness threshold.26 These findings highlight the potential for gender-neutral vaccination to strengthen HPV prevention efforts in South Korea and are consistent with recent recommendations for gender-neutral HPV vaccination in Korea51 and policy shifts in several other high-income countries expanding their national programs to include boys.13 Similar HPV modeling studies in other East Asian countries found gender-neutral HPV vaccination to be cost-effective compared to female-only 9vHPV vaccination programs.19,20 Furthermore, gender-neutral immunization with the 9vHPV vaccine has been compared with the existing programs of vaccination of girls (only) with bivalent or quadrivalent HPV vaccines in several European countries.52–54 In these analyses, a program of gender-neutral immunization with the 9vHPV vaccine was projected to reduce the incidence of HPV disease, but the results for cost-effectiveness were mixed: gender-neutral vaccination was projected to be cost-effective in some countries52,53 but not others.54 Comparisons with female-only HPV vaccination indicate that gender-neutral vaccination is, in general, likely to be cost-effective regardless of the specific HPV vaccine.55 This was shown in a modeling study of gender-neutral HPV vaccination in 11 European countries that had existing vaccination programs for girls (with bivalent, 4vHPV, or 9vHPV vaccines).55 One of the factors limiting the cost-effectiveness of gender-neutral vaccination in countries with existing girls-only vaccination programs and high vaccine coverage is the protection males already have through herd immunity.56 For sexually transmitted infections like HPV, herd immunity depends on vaccine coverage in sexually active cohorts, mixing patterns across age and risk groups, and the transmissibility and duration of infection. That is, the incremental benefits of adding vaccination for boys depend on the existing vaccination coverage in girls. In practice, high vaccine coverage among girls produces substantial herd effects that lower HPV prevalence in males, reducing the incremental benefits of male vaccination. However, herd protection is incomplete and uneven: it confers less benefit to populations with lower female coverage, to subgroups with higher sexual activity, and to males who have sexual contact with unvaccinated individuals. Gender-neutral vaccination both increases direct protection in boys (reducing male disease burden such as genital warts, RRP, and HPV-attributable cancers) and strengthens herd immunity, accelerating population-level declines in HPV transmission and disease incidence beyond what can be achieved by girls-only programs alone.57 In South Korea, despite a high coverage rate in the existing girls-only vaccination program, we found that gender-neutral HPV vaccination would be cost-effective, reflecting the additional value of direct protection for boys. Still, Min et al. found that cultural perceptions of HPV vaccination as a “cervical cancer vaccine,” limited discussion of sexual health with boys, and misconceptions about HPV’s impact on males in South Korea could limit the expansion of gender-neutral vaccination.51 Recent studies from South Korea’s National Evidence-based Healthcare Collaborating Agency suggest that expanding the current HPV vaccination program to females up to 26 years of age would be cost-effective,58 but that the cost-effectiveness of gender-neutral 9vHPV immunization compared with 4vHPV immunization of girls would depend on vaccine price.26 The results of health-economic modeling studies may vary depending on the structure of the model and the variables included. The model described here included variables not considered in all models, including hysterectomy rates due to cervical cancer. A nuanced approach was taken to modeling the degree of protection conferred by the vaccine, which varied with HPV type and cancer type for transient versus persistent infections and for progression to neoplasia, as well as for males and females. The ICER value calculated here for the 9vHPV vaccine may be an underestimate because it refers only to HPV-related diseases resulting from infection with 9vHPV vaccine HPV types, excluding potential cross-protection against HPV types not covered by the vaccine.59 Our analysis has some limitations. A limitation inherent in modeling HPV diseases is that the models must project events over a long period of time (by consensus, 100 years) to account for the slow progression from initial HPV infection to cancer. Many determinative factors are likely to change over this period. Variations in certain parameters that are among the key drivers of uncertainty in cost-effectiveness evaluations of HPV vaccination (e.g., vaccine price, the discount rate)17 were shown in the sensitivity analysis not to substantively affect the cost-effectiveness ratio. Other model assumptions, including a 100% completion of the second dose course after receiving the first dose, and a lifetime duration of immunity following vaccination, were not examined. Real-world completion may be less than 100% and vaccine-induced immunity could wane over time, potentially reducing long-term effectiveness and cost-effectiveness. Future work should therefore explore scenarios with partial dose completion and waning immunity. In addition, the model does not explicitly capture uncertainty around behavioral inputs over time. Finally, implementation of gender-neutral HPV vaccination may face real-world barriers such as budgetary constraints, vaccine supply, and uptake among boys, which were beyond the scope of this analysis. These factors could influence long-term outcomes and should be addressed in future research. Further studies could also examine the real-world effectiveness after program implementation, catch-up vaccination, and public acceptability in the South Korean context. Conclusions To achieve the World Health Organization’s 90% HPV vaccination target for cervical cancer elimination, South Korea must increase its current vaccination coverage. A gender-neutral vaccination program is an essential strategy to help close this gap, but its adoption is often hindered by cost concerns. This study directly addresses that barrier, providing robust health economic evidence that gender-neutral vaccination is a cost-effective investment for South Korea. Our findings demonstrate that replacing the current program of vaccinating 12-year-old girls with the 4vHPV vaccine with a gender-neutral program using the 9vHPV vaccine would substantially reduce the public health burden of HPV-related diseases in both females and males. Under current assumptions about vaccine price and coverage, gender-neutral vaccination would be cost-effective over a 100-year period. Importantly, even in countries with successful, long-standing female-only vaccination programs, transitioning to a gender-neutral, 9vHPV strategy has been shown to be not only cost-effective but also a necessary step to correct systemic inequities and close critical protection gaps. Given Korea’s distinct demographic and healthcare characteristics, the evidence presented here is particularly impactful in highlighting the urgency of moving toward a gender-neutral 9vHPV vaccination strategy. In addition, evidence from other high-income countries suggests that implementing gender-neutral vaccination programs can generate peer effects, leading to higher vaccine uptake in both sexes. Similar dynamics are anticipated in Korea, which would strengthen population-level immunity and advance gender equity by ensuring that boys – who currently remain largely unvaccinated and vulnerable to HPV-related diseases – receive equal protection. From a policy perspective, prioritizing favorable vaccine pricing and measures to achieve realistic male uptake (e.g., school-based vaccination programs, public communication campaigns) will be key to maximizing cost-effectiveness and ensuring successful implementation. Together, this evidence strongly supports expanding South Korea’s national immunization program to include gender-neutral 9vHPV vaccination as a cost-effective and equitable strategy to reduce the burden of HPV-related diseases and protect the health of both boys and girls. Supplementary Material Supplementary Materials.docx Acknowledgments Medical writing assistance was provided by ScribCo. Biography Isaya Sukarom, PhD, is a Director of Outcomes Research at an MSD subsidiary of Merck & Co., Inc., Rahway, NJ, USA. In this role, she oversees outcomes research and health economics activities related to vaccines across the Asia Pacific region. Dr. Sukarom has authored multiple publications on cost-effectiveness analysis, systematic literature reviews, and the burden of disease in vaccine and infectious disease areas. She earned her PhD in Pharmaceutical Socioeconomics from the University of Iowa. Funding Statement This work was supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Disclosure statement Sangrak Bae works with the Department of Urology, Uijeongbu St.Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. Ji Hyun Park, Seyoung Oh, and Gyongseon Yang are employees of MSD Korea, Seoul, South Korea. Wei Wang and Andrew Pavelyev are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Isaya Sukarom is an employee of MSD Thailand, Bangkok, Thailand. Supplementary materials Supplemental data for this article can be accessed online at https://doi.org/10.1080/21645515.2025.2582299 References Associated Data Supplementary Materials Supplementary Materials.docx